Literature DB >> 17024441

Scleral window surgery and topical mitomycin C for nanophthalmic uveal effusion complicated by renal failure: case report.

Yumi Suzuki1, Sachiko Nishina, Noriyuki Azuma.   

Abstract

PURPOSE: To describe the case of a 16-year-old patient with nanophthalmic uveal effusion associated with renal failure that was treated with scleral window surgery and topical administration of mitomycin C (MMC).
METHODS: Case report.
RESULTS: Total uveal effusion was restored in the nanophthalmic eyes. Partial-thickness scleral flap with deep sclerostomy was performed and topical MMC was administered to one quadrant of the equatorial sclera. The subretinal fluid resorbed gradually.
CONCLUSIONS: Topical MMC might relieve the blocked transscleral outflow of intraocular fluid in the small area of a sclerostomy in young patients with nanophthalmos or in patients with renal failure in whom uveal effusion occurs repeatedly.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17024441     DOI: 10.1007/s00417-006-0403-6

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.535


  6 in total

1.  Nanophthalmic uveal effusion managed with scleral windows and topical mitomycin-C.

Authors:  L Akduman; D A Adelberg; L V Del Priore
Journal:  Ophthalmic Surg Lasers       Date:  1997-04

2.  Uveal effusion syndrome: clinical features, surgical treatment, histologic examination of the sclera, and pathophysiology.

Authors:  M Uyama; K Takahashi; J Kozaki; N Tagami; Y Takada; H Ohkuma; H Matsunaga; T Kimoto; T Nishimura
Journal:  Ophthalmology       Date:  2000-03       Impact factor: 12.079

3.  Bullous retinal detachment associated with renal failure: case report.

Authors:  M Goldstein; I E Kanarek
Journal:  Ann Ophthalmol       Date:  1979-06

4.  Recurrence of nanophthalmic uveal effusion.

Authors:  H Morita; M Funata; T Kusakari; Y Yoshino; M Kiyosawa
Journal:  Ophthalmologica       Date:  1993       Impact factor: 3.250

5.  Uveal effusion syndrome associated with primary pulmonary hypertension and vomiting.

Authors:  L Akduman; L V Del Priore; H J Kaplan; T Meredith
Journal:  Am J Ophthalmol       Date:  1996-05       Impact factor: 5.258

  6 in total
  5 in total

1.  Medical therapy for uveal effusion syndrome.

Authors:  B Andrijević Derk; G Benčić; V Corluka; M Zorić Geber; Z Vatavuk
Journal:  Eye (Lond)       Date:  2014-06-06       Impact factor: 3.775

2.  Scleral punch method with topical mitomycin C for safe revision of failed deep sclerectomy in nanophthalmic uveal effusion syndrome.

Authors:  Nelson A Sabrosa; Henry B Smith; Robert E MacLaren
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-01-08       Impact factor: 3.117

3.  Geographic filling delay of the choriocapillaris in the region of dilated asymmetric vortex veins in central serous chorioretinopathy.

Authors:  Shoji Kishi; Hidetaka Matsumoto; Shozo Sonoda; Takashi Hiroe; Taiji Sakamoto; Hideo Akiyama
Journal:  PLoS One       Date:  2018-11-09       Impact factor: 3.240

4.  Diagnosis and a minimum effective management for nanophthalmic uveal effusion syndrome.

Authors:  Wei Jin; Yaopeng Xu; Wenjun Wang; Anhuai Yang
Journal:  Indian J Ophthalmol       Date:  2016-08       Impact factor: 1.848

5.  Scleral resection in chronic central serous chorioretinopathy complicated by exudative retinal detachment.

Authors:  Pradeep Venkatesh; Rohan Chawla; Koushik Tripathy; Harsh Inder Singh; Ravi Bypareddy
Journal:  Eye Vis (Lond)       Date:  2016-09-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.